The stock of Akebia Therapeutics Incorporated (NASDAQ:AKBA) registered an increase of 1.26% in short interest. AKBA’s total short interest was 2.94M shares in March as published by FINRA. Its up 1.26% from 2.90M shares, reported previously. With 289,800 shares average volume, it will take short sellers 10 days to cover their AKBA’s short positions. The short interest to Akebia Therapeutics Incorporated’s float is 19.06%. The stock is up 0.27% or $0.02 after the news, hitting $7.53 per share. About 8,518 shares traded hands. Akebia Therapeutics Inc (NASDAQ:AKBA) has declined 21.44% since July 27, 2015 and is downtrending. It has underperformed by 17.13% the S&P500.
Akebia Therapeutics, Inc. is a biopharmaceutical company. The company has a market cap of $293.59 million. The Firm is focused on the development of therapeutics based on hypoxia inducible factor biology and the commercialization of these products for patients with kidney disease. It currently has negative earnings. The Company’s lead product candidate, AKB-6548, is being developed as a once-daily, oral therapy.
The institutional sentiment decreased to 1.89 in 2015 Q3. Its down 2.94, from 4.83 in 2015Q2. The ratio turned negative, as 12 funds sold all Akebia Therapeutics Inc shares owned while 15 reduced positions. 19 funds bought stakes while 32 increased positions. They now own 19.74 million shares or 21.59% less from 25.18 million shares in 2015Q2.
Novo A S holds 1.51% of its portfolio in Akebia Therapeutics Inc for 1.52 million shares. P.A.W. Capital Corp owns 130,000 shares or 1.44% of their US portfolio. Moreover, Eam Investors Llc has 0.37% invested in the company for 241,440 shares. The Florida-based Eagle Asset Management Inc has invested 0.22% in the stock. Perceptive Advisors Llc, a New York-based fund reported 260,000 shares.
Since April 6, 2015, the stock had 0 buys, and 2 sales for $21,477 net activity. Hadas Nicole R. sold 1,484 shares worth $12,860. Nash Duane sold 996 shares worth $8,617. Satter Muneer A bought 420,000 shares worth $3.47 million.
Out of 7 analysts covering Akebia Therapeutics Inc (NASDAQ:AKBA), 6 rate it “Buy”, 0 “Sell”, while 1 “Hold”. This means 86% are positive. Akebia Therapeutics Inc was the topic in 8 analyst reports since August 13, 2015 according to StockzIntelligence Inc. Credit Suisse initiated the stock on January 21 with “Neutral” rating.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.